Related Experiment Video
Updated: Jul 16, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Knowledge and management of metabolic dysfunction-associated steatotic liver disease among endocrinologists in Spain
María Teresa Julián1, Miguel A Rubio-Herrera2, Javier Escalada3
1Servicio de Endocrinología y Nutrición, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain.
Background:
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease and is closely associated with type 2 diabetes mellitus (T2DM) and obesity. However, it continues to have limited clinical visibility outside the field of Hepatology.
Objective:
To evaluate knowledge, liver fibrosis screening practices, and perceived barriers related to MASLD among endocrinologists in Spain.
Materials And Methods:
An exploratory cross-sectional observational study was conducted using an online survey promoted by the MASLD Working Group of the Spanish Society of Endocrinology and Nutrition (SEEN) and addressed to all society members. A total of 210 anonymized surveys were analyzed, collecting information on: liver fibrosis screening in patients with T2DM and/or obesity, diagnostic tools used, availability of clinical protocols, access to liver elastography, and the main barriers to MASLD management. A descriptive analysis of the results was performed.
Results:
Approximately half of the endocrinologists reported performing liver fibrosis screening in patients with T2DM or obesity. FIB-4 was the most frequently used screening tool (78.4%), although automated calculation was available in only 60.8% of centers. Lack of time, insufficient training, and limited protocol availability (31.6%) were identified as the main barriers, and direct access to elastography from Endocrinology departments was limited.
Conclusions:
This exploratory study shows that MASLD is not yet fully integrated into endocrinology practice in Spain. The lack of systematic screening, together with organisational and educational barriers, limits the early detection of hepatic fibrosis in high-risk populations. Strengthening awareness, training, and protocol development is necessary to integrate liver health into the comprehensive management of patients with metabolic disease.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:30Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can also...
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...